摘要
体外制备严重急性呼吸综合征冠状病毒2(SARS-CoV-2)类病毒细胞株,用不同浓度莪术油处理类病毒细胞株,观察检测细胞数和相对荧光值(RLU),计算其半数有效抑制浓度(IC50);临床纳入新型冠状病毒肺炎患者4例,对照组和试验组各2例,对照组常规治疗,试验组在常规治疗的基础上联用莪术油注射液,观察患者核酸转阴率、转阴时间、肺部影像学变化、退热时间、临床改善时间和不良事件发生情况等。体外实验,随着莪术油浓度增加,相对荧光值逐渐降低,与对照组比较,差异有统计学意义(P<0.05),IC50值为0.26μg/ml;体内研究:试验组病例1粪便新型冠状病毒核酸3 d转阴,病例2咳嗽症状明显缓解,观察肺部影像学有明显吸收;对照组咽拭子新型冠状病毒核酸转阴时间分别为5、7 d。试验组均无不良事件发生。莪术油体外对SARS-CoV-2类病毒具有较强抑制作用,且具有浓度依赖性。COVID-19在常规治疗的基础上联用莪术油注射液可改善患者因SARS-CoV-2感染引起的咳嗽、促进SARS-CoV-2转阴及肺部病灶吸收,降低肺损伤,且未产生明显的不良事件。
To study the antiviral effect of Zedoary Turmeric Oil Injection on novel coronavirus,SARS-CoV-2 viroid cell lines were prepared in vitro and treated with different concentrations of Zedoary Oil.The cell number and relative fluorescence value(RLU)were observed and measured,and the 50%effective inhibitory concentration(IC 50)was calculated.Four patients with Coronavirus Disease 2019 were clinically included,including 2 in the control group and 2 in the experimental group.The control group received conventional treatment,and the experimental group received Zedoary Turmeric Oil Injection in addition to conventional treatment.The nucleic acid conversion rate,conversion time,pulmonary imaging changes,fever reduction time,clinical improvement time and adverse events of the patients were observed.In vitro experiment,the relative fluorescence value decreased with increasing concentration of Zedoary Turmeric Oil,which was significantly different from that of the control group(P<0.05).The IC50 was 0.26μg/ml.In vivo study,the novel coronavirus nucleic acid in stool of case 1 in the test group turned negative in 3 days,the cough symptom of case 2 was significantly relieved,and there was obvious absorption in pulmonary imaging.The negative conversion time of novel coronavirus nucleic acid in the control group was 5 and 7 days respectively.No adverse events occurred in the experimental group.Zedoary Turmeric Oil had strong inhibitory effect on SARS-COV-2 virus in vitro which was dose-dependent.In vivo treatment of COVID-19,Zedoary Turmeric Oil Injection combined with conventional treatment can improve the cough caused by SARS-COV-2 infection,promote SARS-COV-2 to turn negative,promote absorption of lung lesions,and reduce lung injury,with no obvious adverse events.
作者
周园园
戴志娟
张淑君
李岳春
戴元荣
王贺
吴海林
冯梦晴
李校堃
黄晓晖
朱光辉
Zhou Yuanyuan;Dai Zhijuan;Zhang Shujun;Li Yuechun;Dai Yuanrong;Wang He;Wu Hailin;Feng Mengqing;Li Xiaokun;Huang Xiaohui;Zhu Guanghui(School of Pharmacy,Anhui Medical University,Hefei 230032;Dept of Pharmacy,The Second Affiliated Hospital of Wenzhou Medical University,Wenzhou 325035;Dept of Respiratory Medicine,The Second Affiliated Hospital of Wenzhou Medical University,Wenzhou 325035;School of Chinese Materia Medica,Shanghai University of Chinese Medicine,Shanghai 201203;Hefei Future Drug Development Co.LTD,Hefei 242811;Hefei Zhongkupresen Biomedical Technology Co.LTD,Hefei 242811;School of Pharmacy,Wenzhou Medical University,Wenzhou 325035)
出处
《安徽医科大学学报》
CAS
北大核心
2022年第4期664-667,672,共5页
Acta Universitatis Medicinalis Anhui
基金
浙江大学新型冠状病毒肺炎(COVID-19)应急科研专项(编号:2020XGZX029)
温州市新型冠状病毒肺炎疫情防控应急攻关项目(编号:ZY202002)
温州新型冠状病毒肺炎回溯性流调研究(编号:2020C03131)。
